William McKee
CIK 1237262 · Chief Financial Officer · last filed 2026-06-16
William McKee is a Chief Financial Officer who has filed 48 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for ASRT, was dated Jun 16, 2026. Across all open-market trades the lifetime net is −$763.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $14.6K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AUXL price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Assertio Holdings, Inc. (ASRT) Delisted | Director | 0 | $23.50 | $0 | -$220.9K | 13 | 2026-06-16 |
| Rein Therapeutics, Inc. (ALRN) Delisted | Director | — | $2.11 | — | $0 | 4 | 2022-06-17 |
| CCCC | Chief Financial Officer | 5,263 | $2.77 | $14.6K | $100.0K | 1 | 2020-10-06 |
| AGILE THERAPEUTICS INC (AGRX) Delisted | Director | 9 | $1.51 | $14 | $0 | 5 | 2019-06-07 |
| Assertio Therapeutics, Inc (DEPO) Delisted | Director | — | — | — | $0 | 3 | 2018-05-10 |
| Dare Bioscience, Inc. (CERU) Delisted | Director | 342 | — | — | $0 | 4 | 2017-01-05 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | Director | 0 | — | — | -$642.2K | 9 | 2015-01-30 |
| BARR PHARMACEUTICALS INC (BRL) Delisted | EVP, CFO | 8,977 | — | — | $0 | 7 | 2008-12-19 |
Recent Filings
48 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-16 | Assertio Holdings, Inc. (ASRT) Delisted | Mixed | −27,936 | $0 | EDGAR |
| 2026-05-06 | Assertio Holdings, Inc. (ASRT) Delisted | Grant (A) | +4,851 | $0 | EDGAR |
| 2025-05-09 | Assertio Holdings, Inc. (ASRT) Delisted | Grant (A) | +53,750 | $0 | EDGAR |
| 2024-05-28 | Assertio Holdings, Inc. (ASRT) Delisted | Grant (A) | +53,750 | $0 | EDGAR |
| 2023-08-15 | Assertio Holdings, Inc. (ASRT) Delisted | Sell (S) | −22,000 | -$69.0K | EDGAR |
| 2023-08-14 | Assertio Holdings, Inc. (ASRT) Delisted | Notice (144) | −22,000 | -$69.0K | EDGAR |
| 2023-05-12 | Assertio Holdings, Inc. (ASRT) Delisted | Grant (A) | +31,194 | $0 | EDGAR |
| 2022-06-17 | Rein Therapeutics, Inc. (ALRN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-16 | Assertio Holdings, Inc. (ASRT) Delisted | Sell (S) | −22,322 | -$52.5K | EDGAR |
| 2022-05-06 | Assertio Holdings, Inc. (ASRT) Delisted | Grant (A) | +86,286 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.